Relief is a biopharmaceutical company founded by former Merck executives (Serono division) whose objective is to provide patients with therapeutic relief in serious diseases with high unmet medical need.
We focus on clinical-stage programs based on molecules of natural origin (peptides and proteins) with a history of clinical use (well-established safety and tolerability) and either initial human activity with efficacy data (proof-of-concept) or a strong scientific rationale. Our most advanced programs involve our lead compound RLF-100™, a synthetic human vasoactive intestinal peptide (VIP) with multifaceted mode of action, in respiratory indications: COVID-19 induced lung injury with major near-term milestones and pulmonary sarcoidosis, two diseases for which no transformational therapy exists. Clinical development of RLF-100™ for other indications in both acute and chronic lung diseases are in planning stages.
Since July 2020, severe COVID-19 patients have been treated with intravenous RLF-100™ under U.S. FDA Emergency Use Investigational New Drug (IND) authorization and Expanded Access Protocol authorization for the treatment of respiratory failure in COVID-19 with early promising results. By granting RLF-100™ Expanded Access Protocol, the FDA has made a potentially lifesaving drug immediately available to critically ill patients who have no other available treatment option. The program has been recently submitted for U.S. Emergency Use Authorization. In addition, there are currently two randomized, double-blinded, placebo controlled Phase 2b/3 trials in COVID-19 induced lung injury ongoing in the US. Top-line results from the first Phase 2b/3 study in COVID-19 induced Acute Respiratory Distress Syndrome (ARDS) are expected in Q4 2020.
Jack Weinstein, serves as Chief Financial Officer and Treasurer. He brings over 40 years of executive management expertise in investment banking and consulting in the biopharmaceutical and life sciences industries. Jack has extensive experience in corporate finance, business development as well as FDA regulatory and intellectual property strategies.
Jeremy Meinen, VP Finance and Administration, serves as principal finance and accounting officer. Prior to joining Relief, Jeremy provided financial consulting and controlling services to companies in various industries. Jeremy is a Swiss certified public accountant.
Dr. Gilles Della Corte, M.D., is Chief Medical Officer and responsible for the clinical development of RLF-100™ in Europe as well as interactions with and submissions to regulatory authorities. He brings over 40 years of professional experience including several senior positions at Merck Serono (previously Serono).
Relief is strongly supported by a highly knowledgeable Board of Directors with extensive experience in the healthcare industry and capital markets.
Raghuram (RAM) Selvaraju, Ph.D., MBA, is a Managing Director and Senior Healthcare Analyst in the Equity Research Division of H.C. Wainwright & Co., a New York-based full-service investment bank heavily focused on the healthcare sector. He has over 15 years of experience on Wall Street and previously was a pharmaceutical researcher at Serono in Switzerland. He holds Ph.D. and M.S. degrees from the University of Geneva and an M.B.A. from Cornell University.
Peter Egon de Svastich is a Managing Partner of Global Emerging Markets (GEM) and interfaces with GEM on behalf of Relief in matters related to international business development, private placement opportunities, investor relations and administration of all affiliates and subsidiaries.
Thomaz has held various positions in asset management and capital markets at leading international banks, including UBS, Deutsche Bank, JP Morgan and Credit Suisse.
Their objective was to develop atexakin alfa, a human recombinant version of interleukin-6, for peripheral neuropathies treatment
Sonnet assumed the clinical development of atexakin alfa for the treatment of Peripheral Neuropathies focusing primarily on Chemotherapy-Induced Peripheral Neuropathy (CIPN). Relief retained the legacy asset RLF-100™
The Company began rapidly advancing its proprietary asset RLF-100™ into clinical development and towards approval in COVID-19-induced lung injury